Tip os
Log ind
Mads Krogsgaard Thomsen
Foto: /ritzau/Peter Hove Olesen

Novo chief: ”This is data the world has never seen before”

Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.


BY MARTIN HAVTORN PETERSEN
Offentliggjort 28.06.17 kl. 22:24

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

MSD fined for employee’s LinkedIn post

linkedin.jpg Top picks in English:

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

ALK chief: This is terrific data

Top picks in English:

Even Henrik Jacobi, ALK’s R&D chief, is surprised by the impact of the phase III data the company presented for a tree allergy tablet recently. The tablet can potentially enter the market in 2019.

Leo Pharma announces new results for biologic hope

Top picks in English:

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

Onxeo loses half its market cap after failed cancer study

Top picks in English:

The Danish-French biotech company Onxeo did not succeed with a phase III trial with drug candidate Livataq in patients with hepatocellular carcinoma (HCC). Now, the share price has dropped by nearly 50 percent and several banks have downgraded the price target of the Onxeo share.

Danish biotech company sold to Swedes

Top picks in English:

The Swedish company Ascelia, managed by a former Sunstone director, has acquired the biotech company Oncoral and its cancer candidate, which is currently being tested in phase I trials at Herlev Hospital in Denmark.

Forsiden lige nu

Coloplast-chef: »Vi føler os overbeviste om, at vi har fat i noget, som kan gøre en forskel«

Oliver Johansen_5718.jpg Medico & Rehab:

Interview: Det danske medicoselskab Coloplast vil hæve barren for innovation og på den måde få bedre fat om særligt modne markeder som USA og Europa. Risikoen ved at lade være er for stor, lyder rationalet.

Senator kvæler Trumps sidste håb om at ophæve Obamacare

Medicinal & Biotek:

Tre nej-stemmer fra republikanske senatorer har formentlig endegyldigt begravet præsident Donald Trumps planer om at tilbagerulle den tidligere præsident Barack Obamas sundhedsreform.

Allergan får ikke lov at indsende ansøgning for skizofrenimiddel

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder vil ikke acceptere en ny ansøgning for et skizofrenimiddel fra det irsk-baserede selskab Allergan. Midlet er for få måneder siden blevet godkendt i Europa.

Minister: Brug for mere kapital til startups på sundhedsområdet

Medicinal & Biotek:

Det skal være nemmere for danske iværksættere og mindre startups at rejse kapital og søge fonde om støtte, mener erhvervsministeren, der efterspørger flere fonde med entydigt fokus på sundhedsområdet. Industrien, DTU-professor og Vækstfonden bakker op.

Danmark har budt 1,7 mia. kr. på EU-agentur

Sygdom & Sundhed:

Regeringen har tilbudt EU at betale 1,7 milliarder kroner i driftsudgifter til EU's lægemiddelagentur. Men SF og DF sår tvivl om den brede opbakning.

Finanshus: Usikkert hvad investorerne får ud af Össurs besparelser

Medico & Rehab:

Selvom det er positivt, at Össur vil til at spare 10 mio. kr. om året på effektiviseringer, så er det endnu uvist, hvilken effekt det vil have på selskabets investorer.

ANNONCE
ANNONCE


ANNONCE